Helicobacter Pylori Eradication

Is There Any Advantage of Treating Partners in Helicobacter Pylori Eradication?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN36321686

Enrollment

100

Registered

2014-12-10

Start date

2013-01-13

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori (HP) infection Infections and Infestations Helicobacter pylori

Interventions

The participants were randomised into two groups: Group 1: HP-positive patients and HP-positive partners were treated with levofloxacin 500 mg daily, amoxicillin 1g b.i.d and lansopra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Helicobacter pylori positive patients and their partners

Exclusion criteria

Exclusion criteria: People who are Helicobacter pylori negative

Design outcomes

Primary

Measure	Time frame
Eradication success rate	—

Secondary

Measure	Time frame
Re-infection rate between partners	—

Countries

Turkey

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026